东北制药
(000597)
| 流通市值：66.24亿 | | | 总市值：68.88亿 |
| 流通股本：13.74亿 | | | 总股本：14.29亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,940,260,731.63 | 8,243,175,021.66 | 6,403,932,985.84 | 4,506,385,834.6 |
| 营业收入 | 1,940,260,731.63 | 8,243,175,021.66 | 6,403,932,985.84 | 4,506,385,834.6 |
| 二、营业总成本 | 1,819,082,084.79 | 7,664,281,359.63 | 6,025,475,847.75 | 4,251,355,564.81 |
| 营业成本 | 1,199,322,797.06 | 4,890,195,587.9 | 3,782,424,782.39 | 2,570,416,413.41 |
| 税金及附加 | 17,668,801.54 | 81,746,979.15 | 61,878,042.36 | 43,104,937.7 |
| 销售费用 | 386,749,043.1 | 1,809,716,724.85 | 1,480,467,637.25 | 1,108,704,515.1 |
| 管理费用 | 204,145,159.73 | 815,553,307.45 | 708,522,450.51 | 562,043,687.25 |
| 研发费用 | 17,035,942.04 | 97,041,920.16 | 42,261,667.57 | 24,984,288.41 |
| 财务费用 | -5,839,658.68 | -29,973,159.88 | -50,078,732.33 | -57,898,277.06 |
| 其中:利息费用 | 17,896,368.05 | 77,391,725.08 | 56,695,393.89 | 40,320,335.26 |
| 其中:利息收入 | 25,685,182.2 | 155,080,614.29 | 123,515,209.35 | 100,931,042.56 |
| 加:投资收益 | 2,273,334.53 | 8,605,948.49 | 8,293,014.28 | 7,623,330.54 |
| 资产处置收益 | 6,653.37 | 172,209.96 | 172,907.13 | 173,919.36 |
| 资产减值损失(新) | -37,669,636.92 | -193,491,641.88 | -138,662,439.55 | -126,116,630.41 |
| 信用减值损失(新) | 257,502.93 | 6,786,090.19 | 2,962,158.67 | 952,077.51 |
| 其他收益 | 31,621,808.89 | 97,259,421.64 | 62,513,022.14 | 52,895,333.93 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 117,668,309.64 | 498,225,690.43 | 313,735,800.76 | 190,558,300.72 |
| 加:营业外收入 | 2,363,020.96 | 28,991,702.42 | 15,085,454.68 | 8,015,354.93 |
| 减:营业外支出 | 3,596,740 | 39,045,243.43 | 25,179,043.59 | 4,526,808.91 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 116,434,590.6 | 488,172,149.42 | 303,642,211.85 | 194,046,846.74 |
| 减:所得税费用 | 56,653,590.5 | 112,193,777.5 | 69,171,723.26 | 49,217,797.52 |
| 六、净利润 | 59,781,000.1 | 375,978,371.92 | 234,470,488.59 | 144,829,049.22 |
| 持续经营净利润 | 59,781,000.1 | 375,978,371.92 | 234,470,488.59 | 144,829,049.22 |
| 归属于母公司股东的净利润 | 57,633,861.05 | 358,458,434.72 | 219,779,877.85 | 134,886,215.06 |
| 少数股东损益 | 2,147,139.05 | 17,519,937.2 | 14,690,610.74 | 9,942,834.16 |
| (一)基本每股收益 | 0.04 | 0.25 | 0.15 | 0.09 |
| (二)稀释每股收益 | 0.04 | 0.25 | 0.15 | 0.09 |
| 八、其他综合收益 | 66,128.96 | 921,943.04 | 1,417,693.13 | 1,617,003.89 |
| 归属于母公司股东的其他综合收益 | 66,473.06 | 919,414.3 | 1,417,770.49 | 1,618,308.27 |
| 九、综合收益总额 | 59,847,129.06 | 376,900,314.96 | 235,888,181.72 | 146,446,053.11 |
| 归属于母公司股东的综合收益总额 | 57,700,334.11 | 359,377,849.02 | 221,197,648.34 | 136,504,523.33 |
| 归属于少数股东的综合收益总额 | 2,146,794.95 | 17,522,465.94 | 14,690,533.38 | 9,941,529.78 |
| 公告日期 | 2024-04-26 | 2024-03-30 | 2023-10-27 | 2023-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |